About ManagedLab

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium dolemue launti totam aperiam, eaque ipsa quae abillo. Invente veriatis et quasi.

Organovo Halts Liver Tissue R&D, Plans Restructuring to Cut Costs

Posted by |2019-08-07T13:58:31-07:00August 7th, 2019|

Organovo says it has run out of money to advance its efforts to develop 3-D “patches” of living human liver tissue to tide over people waiting for an organ transplant. The San Diego-based biotech has been working since 2007 to use a method known as bio-printing to come up with such a product, which Organovo […]

Women’s Health-Focused Luca Bio Takes Microbiome R&D Beyond the Gut

Posted by |2019-08-06T14:38:24-07:00August 6th, 2019|

Urinary tract infections are among the most common bacterial infections in the United States, but treatment options are shrinking as resistance to antibiotics commonly prescribed to treat the condition continues to rise. Luca Biologics, a new Cambridge, MA-based biotech focused on women’s health, emerged Tuesday with a plan to advance an investigational UTI drug into […]

Another Delay for Intra-Cellular as FDA Extends Review of Psych Drug

Posted by |2019-08-05T08:06:30-07:00August 5th, 2019|

[Updated 1:33 p.m.] Intra-Cellular Therapies will have to wait another three months to see whether the FDA will approve its experimental drug for schizophrenia, which has produced mixed results in human studies but is currently under a regulatory review. The New York company said Monday that the FDA has pushed back the deadline for its […]

Acadia, Neurocrine See Stock Price Bump After Quarterly Earnings

Posted by |2019-08-05T03:30:05-07:00August 2nd, 2019|

We’re in the midst of earnings season, and a couple of San Diego’s publicly traded biotechs recently updated investors this week with sales data and other financial insights. Here’s a look at those companies. —Acadia Pharmaceuticals faced a setback in July with the failure of a late-stage trial that was testing pimavanserin—which the company’s sells […]

Adverum Biotechnologies Executive Mehdi Gasmi to Retire

Posted by |2019-08-01T14:08:25-07:00August 1st, 2019|

Gene therapy developer Adverum Biotechnologies (NASDAQ: ADVM) announced Thursday that Mehdi Gasmi, the company’s president and chief scientific officer, is retiring. When Gasmi retires on Sept. 16, he will join the Menlo Park, CA, company’s board of directors. He will also serve as a consultant to the business for six months. Adverum says a search […]

Pfizer’s Avagliano Joins G1 Therapeutics as Chief Business Officer

Posted by |2019-07-31T10:39:22-07:00July 31st, 2019|

G1 Therapeutics (NASDAQ: GTHX) has tapped Mark Avagliano to become its chief business officer. Avagliano joins the Research Triangle Park, NC-based cancer drug developer from Pfizer (NYSE: PFE), where he was vice president of corporate development. Lead G1 drug candidate trilaciclib, which has been tested in small-cell lung cancer and metastatic triple-negative breast cancer, is […]

Illumina Cuts Forecasts As Consumer Tests, Genomics Initiatives Lag

Posted by |2019-07-30T14:26:11-07:00July 30th, 2019|

About this time last year, DNA sequencing giant Illumina upped its financial projections, estimating its sales would grow 20 percent year-over-year. It exceeded that goal, with revenue rising 21 percent to $3.33 billion by the end of 2018. It’s a different financial story this summer. On Monday, Illumina (NASDAQ: ILMN) informed the markets that it […]

Turning Point Therapeutics Taps Investment Banker Yi Larson as CFO

Posted by |2019-07-29T12:19:04-07:00July 29th, 2019|

Turning Point Therapeutics (NASDAQ: TPTX) has hired one of the investment bankers who guided it to the public markets earlier this year as its chief financial officer. Yi Larson, a managing director at New York-based investment bank Goldman Sachs (NYSE: GS), where she has worked for about 12 years, most recently led its healthcare investment […]

Verb Surgical Taps Kurt Azarbarzin for CEO Role

Posted by |2019-07-29T03:30:06-07:00July 26th, 2019|

Surgical robot developer Verb Surgical has appointed Kurt Azarbarzin to serve as its new CEO. He joins Mountain View, CA-based Verb from CONMED, where he was chief technology officer. Azarbarzin’s experience also includes senior roles at SurgiQuest, Tyco Healthcare, and Covidien. Azarbarzin succeeds former Verb CEO Scott Huennekens, who left the company at the end […]

Obsidian Appoints Stehman-Breen Chief Development Officer

Posted by |2019-07-25T08:16:13-07:00July 25th, 2019|

Catherine Stehman-Breen is joining Obsidian Therapeutics as chief development officer. She was most recently an entrepreneur in residence at Atlas Venture, where she held the chief medical officer positions at Dyne Therapeutics and Disarm Therapeutics, two of the venture capital firm’s portfolio companies. Stehman-Breen’s experience also includes posts at Sarepta Therapeutics (NASDAQ: SRPT), Regeneron Pharmaceuticals […]

Bristol, With Another Lung Cancer Flop, Loses More Ground to Merck

Posted by |2019-07-24T14:10:24-07:00July 24th, 2019|

Bristol-Myers Squibb (NYSE: BMY) this afternoon revealed yet another setback for its cancer immunotherapy nivolumab (Opdivo) in lung cancer, boosting the outlook for rival Merck. The New York pharma giant said that a regimen of nivolumab (Opdivo) and chemotherapy failed to extend the lives of non-squamous, non-small cell lung cancer patients compared to chemo alone […]

Proteostasis Names Gilmartin Chief Medical Officer, Succeeding Lee

Posted by |2019-07-23T09:06:01-07:00July 23rd, 2019|

Geoffrey Gilmartin is taking on a new role at Proteostasis Therapeutics (NASDAQ: PTI) as its chief medical officer. He will succeed Po-Shun Lee, who will become a consultant to the Boston-based cystic fibrosis (CF) drug developer after serving in the CMO role for the past four years. Gilmartin joined Proteostasis in 2016 as chief development […]

Load More Posts